CN Patent

CN110256421A — Kras-g12c抑制剂

Assigned to Wigen Biomedicine Technology Shanghai Co Ltd · Expires 2019-09-20 · 7y expired

What this patent protects

本发明提供了G12C突变体K‑Ras蛋白不可逆抑制剂，本发明还公开了上述G12C突变体K‑Ras蛋白不可逆抑制剂及其制备方法和用途。

USPTO Abstract

本发明提供了G12C突变体K‑Ras蛋白不可逆抑制剂，本发明还公开了上述G12C突变体K‑Ras蛋白不可逆抑制剂及其制备方法和用途。

Drugs covered by this patent

Lumakras (SOTORASIB) · Amgen

Patent Metadata

Patent number: CN110256421A
Jurisdiction: CN
Classification: —
Expires: 2019-09-20
Drug substance claim: No
Drug product claim: No
Assignee: Wigen Biomedicine Technology Shanghai Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.